Snehal Patel Buys 1,500 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel bought 1,500 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The shares were bought at an average price of $14.63 per share, for a total transaction of $21,945.00. Following the completion of the acquisition, the chief executive officer now owns 5,536,102 shares in the company, valued at approximately $80,993,172.26. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Snehal Patel also recently made the following trade(s):

• On Monday, August 5th, Snehal Patel bought 5,500 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $13.18 per share, for a total transaction of $72,490.00.
• On Tuesday, July 23rd, Snehal Patel bought 1,500 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $15.89 per share, for a total transaction of $23,835.00.

Greenwich LifeSciences Stock Down 3.5 %

Shares of NASDAQ GLSI opened at $13.86 on Wednesday. Greenwich LifeSciences, Inc. has a fifty-two week low of $7.58 and a fifty-two week high of $21.44. The business has a 50 day moving average price of $14.39 and a two-hundred day moving average price of $15.02. The firm has a market cap of $178.52 million, a PE ratio of -19.25 and a beta of 1.61.

Greenwich LifeSciences (NASDAQ:GLSI) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.20) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.20). On average, analysts anticipate that Greenwich LifeSciences, Inc. will post -0.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright raised their target price on Greenwich LifeSciences from $36.00 to $38.00 and gave the company a “buy” rating in a report on Friday, August 23rd.

Institutional Investors Weigh In On Greenwich LifeSciences

A number of hedge funds have recently bought and sold shares of the business. Rhumbline Advisers acquired a new stake in Greenwich LifeSciences during the 2nd quarter valued at approximately $117,000. Bank of New York Mellon Corp acquired a new position in shares of Greenwich LifeSciences in the 2nd quarter worth approximately $264,000. Finally, Vanguard Group Inc. grew its position in shares of Greenwich LifeSciences by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock worth $4,449,000 after acquiring an additional 1,420 shares in the last quarter. Institutional investors and hedge funds own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.